TY  - JOUR
AU  - Tang, Kang
AU  - Sun, Qianru
AU  - Zeng, Jinfeng
AU  - Tang, Jing
AU  - Cheng, Peiwen
AU  - Qiu, Zekai
AU  - Long, Haoyu
AU  - Chen, Yilin
AU  - Zhang, Chi
AU  - Wei, Jie
AU  - Qiu, Xiaoping
AU  - Jiang, Guozhi
AU  - Fang, Qianglin
AU  - Sun, Litao
AU  - Sun, Caijun
AU  - Du, Xiangjun
TI  - Network-based approach for drug repurposing against mpox.
JO  - International journal of biological macromolecules
VL  - 270
IS  - Pt 2
SN  - 0141-8130
CY  - New York, NY [u.a.]
PB  - Elsevier
M1  - DKFZ-2024-01060
SP  - 132468
PY  - 2024
AB  - The current outbreak of mpox presents a significant threat to the global community. However, the lack of mpox-specific drugs necessitates the identification of additional candidates for clinical trials. In this study, a network medicine framework was used to investigate poxviruses-human interactions to identify potential drugs effective against the mpox virus (MPXV). The results indicated that poxviruses preferentially target hubs on the human interactome, and that these virally-targeted proteins (VTPs) tend to aggregate together within specific modules. Comorbidity analysis revealed that mpox is closely related to immune system diseases. Based on predicted drug-target interactions, 268 drugs were identified using the network proximity approach, among which 23 drugs displaying the least side-effects and significant proximity to MPXV were selected as the final candidates. Lastly, specific drugs were explored based on VTPs, differentially expressed proteins, and intermediate nodes, corresponding to different categories. These findings provide novel insights that can contribute to a deeper understanding of the pathogenesis of MPXV and development of ready-to-use treatment strategies based on drug repurposing.
KW  - Comorbidity (Other)
KW  - Drug repurposing (Other)
KW  - Mpox (Other)
KW  - Virushost interaction (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38761900
DO  - DOI:10.1016/j.ijbiomac.2024.132468
UR  - https://inrepo02.dkfz.de/record/290332
ER  -